LLY

985.76

+1.21%↑

JNJ

223.6

+0.4%↑

ABBV

205.36

+0.4%↑

UNH

382.72

+1.72%↑

AZN

184.08

-0.73%↓

LLY

985.76

+1.21%↑

JNJ

223.6

+0.4%↑

ABBV

205.36

+0.4%↑

UNH

382.72

+1.72%↑

AZN

184.08

-0.73%↓

LLY

985.76

+1.21%↑

JNJ

223.6

+0.4%↑

ABBV

205.36

+0.4%↑

UNH

382.72

+1.72%↑

AZN

184.08

-0.73%↓

LLY

985.76

+1.21%↑

JNJ

223.6

+0.4%↑

ABBV

205.36

+0.4%↑

UNH

382.72

+1.72%↑

AZN

184.08

-0.73%↓

LLY

985.76

+1.21%↑

JNJ

223.6

+0.4%↑

ABBV

205.36

+0.4%↑

UNH

382.72

+1.72%↑

AZN

184.08

-0.73%↓

Home・Aktien・Beam Therapeutics Inc
Search

Beam Therapeutics Inc

Open

BrancheGesundheitswesen

31.39 -5.62

Starkes Kaufsignal

Kursupdate 12. Mai 2026, 14:25 UTC

BuySell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

30.73

Max

34.08

Schlüsselkennzahlen

By Trading Economics

Einkommen

357M

244M

Verkäufe

104M

114M

Gewinnspanne

214.091

Angestellte

511

EBITDA

368M

261M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+54.7% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

216M

3.1B

Vorheriger Eröffnungskurs

37.01

Vorheriger Schlusskurs

31.39

Nachrichtenstimmung

By Acuity

21%

79%

57 / 346 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

16.225 / 20.17 Unterstützung & Widerstand

Beam Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Mai 2026, 22:15 UTC

Akquisitionen, Fusionen, Übernahmen

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

DJ

Lesen

11. Mai 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

DJ

Lesen

11. Mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

DJ

Lesen

11. Mai 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

DJ

Lesen

11. Mai 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

DJ

Lesen

11. Mai 2026, 22:32 UTC

Ergebnisse

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

DJ

Lesen

11. Mai 2026, 22:02 UTC

Market Talk

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

DJ

Lesen

11. Mai 2026, 21:49 UTC

Ergebnisse

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

DJ

Lesen

11. Mai 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

DJ

Lesen

11. Mai 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

DJ

Lesen

11. Mai 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

DJ

Lesen

11. Mai 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

DJ

Lesen

11. Mai 2026, 21:32 UTC

Akquisitionen, Fusionen, Übernahmen

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

DJ

Lesen

11. Mai 2026, 21:31 UTC

Akquisitionen, Fusionen, Übernahmen

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

DJ

Lesen

11. Mai 2026, 21:23 UTC

Akquisitionen, Fusionen, Übernahmen

CSG Systems Sale to NEC Gets CFIUS Clearance

DJ

Lesen

11. Mai 2026, 21:12 UTC

Ergebnisse

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

DJ

Lesen

11. Mai 2026, 21:12 UTC

Ergebnisse

Ovintiv 1Q Loss/Shr $2.35 >OVV

DJ

Lesen

11. Mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Lesen

11. Mai 2026, 20:44 UTC

Ergebnisse

Steris: Board Approves New $1B Shr Repurchase Program >STE

DJ

Lesen

11. Mai 2026, 20:43 UTC

Ergebnisse

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

DJ

Lesen

11. Mai 2026, 20:32 UTC

Ergebnisse

CleanSpark 2Q Loss/Shr $1.52 >CLSK

DJ

Lesen

11. Mai 2026, 20:32 UTC

Ergebnisse

CleanSpark 2Q Rev $136.4M >CLSK

DJ

Lesen

11. Mai 2026, 20:30 UTC

Ergebnisse

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

DJ

Lesen

11. Mai 2026, 20:30 UTC

Ergebnisse

Steris 4Q Cont Ops EPS $2.24 >STE

DJ

Lesen

11. Mai 2026, 20:30 UTC

Ergebnisse

Steris 4Q Rev $1.6B >STE

DJ

Lesen

11. Mai 2026, 20:30 UTC

Ergebnisse

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

DJ

Lesen

11. Mai 2026, 20:30 UTC

Ergebnisse

Steris 4Q Adj EPS $2.83 >STE

DJ

Lesen

11. Mai 2026, 20:22 UTC

Heiße Aktien

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

DJ

Lesen

11. Mai 2026, 19:37 UTC

Ergebnisse

More Bad News at KKR's Private Credit Fund -- Barrons.com

DJ

Lesen

11. Mai 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

DJ

Lesen

Peer-Vergleich

Kursveränderung

Beam Therapeutics Inc Prognose

Kursziel

By TipRanks

54.7% Vorteil

12-Monats-Prognose

Durchschnitt 50 USD  54.7%

Hoch 80 USD

Tief 26 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Beam Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

11

Buy

1

Halten

0

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Beam Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

16.225 / 20.17Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Mittelfristig

Very Strong Bearish Evidence

All events are bearish.

Langfristig

Bearish Evidence

All events are bearish.

Stimmung

By Acuity

57 / 346 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Andere Aktien aus dem Sektor

LLY

Eli Lilly and Co.

985.76

↑ +1.21%

JNJ

Johnson and Johnson

223.6

↑ +0.4%

ABBV

AbbVie Inc

205.36

↑ +0.4%

UNH

UnitedHealth Group Inc

382.72

↑ +1.72%

AZN

AstraZeneca PLC

184.08

↓-0.73%
help-icon Live chat